Eugene

[email protected]

LATEST

Novartis, Pfizer, Otsuka Lead Pipeline News
By

By
A roundup of the latest market developments from the pipelines of the pharmaceutical majors, featuring news from Novartis, Pfizer, and Otsuka Pharmaceuticals. Editor’s Note: This article was updated on a…

GSK Completes $13-Billion Buy of Novartis’ Stake in Consumer Healthcare JV
By

By
GlaxoSmithKline (GSK) has completed its acquisition of Novartis’ 36.5% stake in the companies’ consumer healthcare joint venture for $13 billion, which grants GSK full ownership of the business. The deal,…

France’s Adocia Partners with China’s Tonghua Dongbao for Insulin Supply
By

By
Adocia, a Lyon, France-headquartered biopharmaceutical company developing new formulations for approved therapeutic proteins, has expanded its pact with Tonghua Dongbao, a Tonghua, China-based pharmaceutical product provider, for Tonghua Dongbao to…

FDA Proposes Ways to Further Address Drug Shortages
By

By
US Food and Drug Administration (FDA) Commissioner Scott Gottlieb has outlined further steps that the agency is considering to better address drug shortage problems, including improving technology, increasing information-sharing requirements,…

FDA Proposes Process Modernization to Support New Drug Development
By

By
The US Food and Drug Administration has proposed changes to modernize the new drug regulatory program through process changes and organizational restructuring. Overall, the FDA estimates the changes will improve…

Catalent, InterveXion in mAb Supply Pact
By

By
Catalent Pharma Solutions reports on its supply pact with InterveXion, a Little Rock, Arkansas-headquartered clinical-stage biopharmaceutical company, to support the production of IXT-m200, InterveXion’s investigational anti-methamphetamine antibody. Catalent has supported…

Cambrex To Invest $5 Million in New Lab at API Site
By

By
Cambrex, an East Rutherford, New Jersey-based contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), plans to begin a $5-million expansion of laboratory facilities at its site in Karlskoga, Sweden.  …

Amgen, MD Anderson Partner in Two Oncology Pacts
By

By
Amgen and the University of Texas MD Anderson Cancer Center have formed two multi-year collaborations to accelerate development of a variety of Amgen’s early-stage oncology therapies for treating patients with…

Celgene Makes Executive Changes
By

By
In the latest in a series of executive moves, Celgene has appointed David V. Elkins as Executive Vice President (EVP) and Chief Financial Officer (CFO). Elkins will join Celgene on…

FDA Issues Complete Response Letter for Amgen’s Biosimilar of Roche’s Herceptin
By

By
The US Food and Drug Administration (FDA) has issued a Complete Response Letter to Amgen regarding its biologics license application for a biosimilar to Roche’s Herceptin (trastuzumab), a cancer drug.…